Company intelligence / Profile preview

Gaia Pharm

Japan

Ownership: Private
Development stage: Other

Overview

GAIA BioMedicine is advancing clinical trials of GAIA-102, an NK-like cell therapy showing interim safety and efficacy data in pediatric neuroblastoma, peritoneal dissemination in gastric/pancreatic cancer, and other pediatric solid tumors.

Therapeutic areas: Oncology
Modalities: Cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Gaia Pharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gaia Pharm.

Explore the full profile